ArticleAdvanced healthcare materials2026
A Naphthalimide-Based NIR-Emissive AIE Photosensitizer for Synergistic Apoptosis/Ferroptosis-Mediated Antitumor Therapy and Broad-Spectrum Bacterial Inactivation With Rapid Wound Healing.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Fluorescence-guided photodynamic therapy (PDT) that targets both malignant cells and pathogenic bacteria is attractive yet challenging, because a single photosensitizer (PS) must combine near-infrared (NIR) emission, efficient reactive oxygen species (ROS) generation, and strong membrane affinity across distinct biological envelopes. Here, we report a donor-π-bridge-engineered series of ionic naphthalimide luminogens, TPA-NIM-M, TPAV-NIM-M, and TPAPV-NIM-M, featuring aggregation-induced emission (AIE) and a cationic membrane-anchoring motif. Among them, TPAPV-NIM-M exhibits far-red/NIR emission, high photostability, and enhanced ROS generation under white-light irradiation through both type I and type II pathways. The extended donor-π conjugation promotes photosensitization, while the ionic amphiphilic structure enables stable plasma membrane (PM) localization, strong membrane binding, and prolonged membrane retention. In cancer cells, photoactivation of TPAPV-NIM-M induces oxidative membrane damage and regulated cell death involving apoptosis and lipid-peroxidation-associated ferroptosis, while allowing real-time fluorescence tracking of membrane blebbing during apoptosis. TPAPV-NIM-M also stains both Gram-negative and Gram-positive bacteria and enables efficient photodynamic bacterial inactivation. In vivo, TPAPV-NIM-M promotes healing in an Escherichia coli-infected wound model and suppresses tumor growth under local light irradiation without apparent systemic toxicity. This work establishes ionic naphthalimide AIEgens as a powerful class of membrane-anchored theranostic agents for image-guided antitumor and antibacterial PDT with broad biomedical potential and translational promise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.